A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

Launched by NOVARTIS PHARMACEUTICALS · Apr 20, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called IAG933 for patients with advanced mesothelioma and certain other types of solid tumors. The main goal of the study is to determine how safe IAG933 is and to find the highest dose that patients can tolerate. This trial is currently recruiting participants who are at least 18 years old and have advanced mesothelioma or other solid tumors that have specific genetic changes, and who have not responded to standard treatments.

To participate, patients must be willing to sign a consent form and undergo a biopsy to provide tumor samples. They should have measurable disease that can be evaluated and must have already tried other treatments for their cancer without success. Participants can expect to receive the study treatment and be closely monitored for any side effects. The trial is designed to help researchers understand how effective and safe this new treatment might be for patients who have limited options left.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed informed consent must be obtained prior to participation in the study.
• • 2. Male or female patients must be ≥ 18 years of age.
• • 3. Dose escalation part: patients with histologically or cytologically confirmed diagnosis of advanced (unresectable or metastatic) mesothelioma or other solid tumors. Patients with solid tumors other than mesothelioma must have local available data for loss-of-function NF2/LATS1/LATS2 genetic alterations (truncating mutation or gene deletion; LATS1/LATS2 mutations will only be included in the dose escalation part), or functional YAP/TAZ fusions. Patients with malignant EHE can be enrolled with only histological confirmation of the disease. Patients must have failed available standard therapies, be intolerant of or ineligible for standard therapy, or for whom no standard therapy exists.
• 4. Dose expansion part: the following patients will be enrolled into 3 different treatment groups:
• • Group 1: Advanced (unresectable or metastatic) MPM patients who have failed available standard therapies for advanced/metastatic disease, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.
• • Group 2: Advanced (unresectable or metastatic) solid tumor patients with available local data for NF2 truncating mutation or deletions. Patient must have failed available standard therapies, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.
• • Group 3: Advanced (unresectable or metastatic) solid tumor patients with available local data for functional YAP/TAZ fusions. EHE patients can be included with only histological confirmation of the disease. Patient must have failed available standard therapies, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.
• • Group 4: Advanced (unresectable or metastatic) non-pleural mesothelioma patients who have failed available standard therapies for advanced/metastatic disease, are intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.
• • 5. Presence of at least one measurable lesion according to mRECIST v1.1 for mesothelioma patients, RECIST v1.1 for patients with other solid tumors, or RANO for patients with primary brain tumors.
• • 6. Patient must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening/baseline, and again during therapy on this study. An archival tumor sample may be used at screening. During the dose expansion part of the study, a decision may be made to stop the collection of on-treatment biopsies.
• Exclusion Criteria:
• 1. Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:
• • 1. ≤ 4 weeks for thoracic radiotherapy to lung fields or limited field radiation for palliation within ≤ 2 weeks prior to the first dose of study treatment. An exception to this exists for patients who have received palliative radiotherapy to bone, who must have recovered from radiotherapy-related toxicities but for whom a 2-week washout period is not required.
• • 2. ≤ 4 weeks or ≤ 5 half-lives (whichever is shorter) for biological therapy (including monoclonal antibodies) or continuous or intermittent small molecule therapeutics or any other investigational agent.
• • 3. ≤3 weeks for treatment with cytotoxic agents or ≤ 6 weeks for cytotoxic agents with risk of major delayed toxicities, such as nitrosoureas and mitomycin C.
• • 4. ≤ 4 weeks for immuno-oncologic therapy, such as CTLA4, PD-1, or PD-L1 antagonists
• • 5. Prior treatment with TEAD inhibitor at any time
• • 2. For mesothelioma patients: use of non-invasive antineoplastic therapy (e.g., tumor treating fields, brand name Optune LuaTM) within 2 weeks of the tumor assessment at screening.
• • 3. Malignant disease, other than that being treated in this study.
• • 4. Insufficient renal function at Screening.
• • 5. Clinically significant cardiac disease or risk factors at screening
• • 6. Insufficient bone marrow function at screening.
• • 7. Insufficient hepatic function at screening.
• 8. Patients who have the following laboratory values \> Common Terminology Criteria for Adverse Events (CTCAE) grade 1:
• • 1. Potassium
• • 2. Magnesium
• • 3. Total calcium (corrected for low serum albumin)
• • 9. Known active COVID-19 infection.
• • 10. Pregnant or nursing (lactating) women,
• • 11. Japan only: patients with a history of drug- and/or non-drug-induced interstitial lung disease (ILD) ≥ Grade 2.
• • Other protocol-defined inclusion/exclusion criteria may apply.